中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2014年
6期
410-413
,共4页
孔德刚%卢实春%王孟龙%林栋栋%郭庆良%武聚山%曾道炳%刘源%张毅
孔德剛%盧實春%王孟龍%林棟棟%郭慶良%武聚山%曾道炳%劉源%張毅
공덕강%로실춘%왕맹룡%림동동%곽경량%무취산%증도병%류원%장의
原发性肝癌%个体化综合治疗模式%远期疗效
原髮性肝癌%箇體化綜閤治療模式%遠期療效
원발성간암%개체화종합치료모식%원기료효
Primary hepatic carcinoma%Personalized integrated therapeutic model%Long-term therapeutic effect
目的 探讨个体化综合外科治疗模式下原发性肝癌的远期临床疗效.方法 回顾性分析首都医科大学附属北京佑安医院普外中心2004年3月至2013年9月831例原发性肝癌患者的临床资料.按不同肿瘤分期、病理类型及治疗方式分组,分别计算术后总体生存率和无瘤生存率,并比较分析组间差异.结果 术后获得随访的患者796例,其总体1、3、5年生存率分别为88.6％、71.7％、61.3％,无瘤生存率分别为69.6％,47.9％,38.4％.其中,742例肝细胞癌(HCC)患者1、3、5年生存率为89.6％、73.2％、63.2％;无瘤生存率为72.1％,52.5％,45.5％.全部患者三种治疗方式生存曲线比较:肝移植(LT)组与肝切除组生存期优于射频消融(RFA)组,LT组在60个月后显示出明显生存优势.结论 个体化综合外科治疗模式可以使原发性肝癌的整体治疗疗效得到进一步提高.
目的 探討箇體化綜閤外科治療模式下原髮性肝癌的遠期臨床療效.方法 迴顧性分析首都醫科大學附屬北京祐安醫院普外中心2004年3月至2013年9月831例原髮性肝癌患者的臨床資料.按不同腫瘤分期、病理類型及治療方式分組,分彆計算術後總體生存率和無瘤生存率,併比較分析組間差異.結果 術後穫得隨訪的患者796例,其總體1、3、5年生存率分彆為88.6％、71.7％、61.3％,無瘤生存率分彆為69.6％,47.9％,38.4％.其中,742例肝細胞癌(HCC)患者1、3、5年生存率為89.6％、73.2％、63.2％;無瘤生存率為72.1％,52.5％,45.5％.全部患者三種治療方式生存麯線比較:肝移植(LT)組與肝切除組生存期優于射頻消融(RFA)組,LT組在60箇月後顯示齣明顯生存優勢.結論 箇體化綜閤外科治療模式可以使原髮性肝癌的整體治療療效得到進一步提高.
목적 탐토개체화종합외과치료모식하원발성간암적원기림상료효.방법 회고성분석수도의과대학부속북경우안의원보외중심2004년3월지2013년9월831례원발성간암환자적림상자료.안불동종류분기、병리류형급치료방식분조,분별계산술후총체생존솔화무류생존솔,병비교분석조간차이.결과 술후획득수방적환자796례,기총체1、3、5년생존솔분별위88.6％、71.7％、61.3％,무류생존솔분별위69.6％,47.9％,38.4％.기중,742례간세포암(HCC)환자1、3、5년생존솔위89.6％、73.2％、63.2％;무류생존솔위72.1％,52.5％,45.5％.전부환자삼충치료방식생존곡선비교:간이식(LT)조여간절제조생존기우우사빈소융(RFA)조,LT조재60개월후현시출명현생존우세.결론 개체화종합외과치료모식가이사원발성간암적정체치료료효득도진일보제고.
Objective To investigate the long-term outcomes of patients with primary hepatic carcinoma (PHC) who received personalized integrated surgical therapy.Methods The clinical data of 831 patients with PHC treated at the General Surgery Department of the Capital Medical University Affiliated Beijing Youan Hospital between March 2004 and September 2013 were retrospectively analyzed.The patients were grouped according to tumor staging,pathology and type of operation.The overall survival and tumor free survival rates were calculated and the survival rates in the different groups were compared.Results Of the 796 patients with PHC who received regular follow-up,the 1-,3-,5-year overall survival and tumor free survival rates were 88.6％,71.7％,61.3％ and 69.6％,47.9％,38.4％ respectively.For the 742 patients with hepatocellular carcinoma,the 1-,3-,5-year overall survival and tumor free survival rates were 89.6％,73.2％,63.2％ and 72.1％,52.5％,45.5％ respectively.The liver transplantation (LT) group and the liver resection group had better survival than the radio frequency ablation (RFA) group.The LT group had significantly better survival after 60 months of surgery than the liver resection group.Conclusion The personalized integrated surgical therapeutic model improved the therapeutic efficacy.
